Literature DB >> 8092312

Effect of chronic ANG I-converting enzyme inhibition on aging processes. IV. Cerebral blood flow regulation.

I Lartaud1, T Makki, L Bray-des-Boscs, N Niederhoffer, J Atkinson, B Corman, C Capdeville-Atkinson.   

Abstract

Age-related changes in systemic arterial blood pressure, basal cerebral blood flow (CBF), and CBF regulatory capacity were investigated in awake 6-, 12-, 24-, and 30-mo-old male Wistar (WAG/Rij) rats, one-half of which received the angiotensin I-converting enzyme inhibitor (ACEI) perindopril from 6 mo onward. There was no age-dependent change in mean arterial blood pressure, basal CBF, or cerebrovascular reactivity to hypercapnia, but the lower limit of CBF autoregulation rose from 70 mmHg at 6 and 12 mo to 90 mmHg in 24- and 30-mo-old animals. ACEI lowered mean arterial blood pressure but had no effect on basal CBF or on cerebrovascular reactivity to hypercapnia. ACEI shifted the lower limit of CBF autoregulation to a 20-mmHg-lower level in 12- and 24-mo animals but not in rats treated for 2 yr, i.e., from the ages of 6 to 30 mo. In conclusion, the main age-related change in CBF regulation was an increase in the lower limit of CBF autoregulation to a higher blood pressure level. Treatment with ACEI partially restored the lower limit of CBF autoregulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092312     DOI: 10.1152/ajpregu.1994.267.3.R687

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

Review 1.  Angiotensin and cerebral blood flow.

Authors:  J M Saavedra; Y Nishimura
Journal:  Cell Mol Neurobiol       Date:  1999-10       Impact factor: 5.046

Review 2.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

Authors:  Juan M Saavedra; Enrique Sánchez-Lemus; Julius Benicky
Journal:  Psychoneuroendocrinology       Date:  2010-10-29       Impact factor: 4.905

Review 3.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

4.  Captopril improves cerebrovascular structure and function in old hypertensive rats.

Authors:  François Dupuis; Jeffrey Atkinson; Patrick Limiñana; Jean-Marc Chillon
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  Effects of chronic and acute aminoguanidine treatment on tail artery vasomotion in ageing rats.

Authors:  A Tabernero; S Nadaud; B Corman; J Atkinson; C Capdeville-Atkinson
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study.

Authors:  J J Claus; M M Breteler; D Hasan; E P Krenning; M L Bots; D E Grobbee; J C van Swieten; F van Harskamp; A Hofman
Journal:  Eur J Nucl Med       Date:  1996-06

7.  Impact of treatment with melatonin on cerebral circulation in old rats.

Authors:  François Dupuis; Olivier Régrigny; Jeffrey Atkinson; Patrick Limiñana; Philippe Delagrange; Elizabeth Scalbert; Jean-Marc Chillon
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

8.  Lineage tracing aged mouse kidneys shows lower number of cells of renin lineage and reduced responsiveness to RAAS inhibition.

Authors:  Hiroko Hamatani; Diana G Eng; Natalya V Kaverina; Kenneth W Gross; Benjamin S Freedman; Jeffrey W Pippin; Stuart J Shankland
Journal:  Am J Physiol Renal Physiol       Date:  2018-02-07

9.  Stroke, high blood pressure and the Renin-Angiotensin-aldosterone system - new developments.

Authors:  Jeffrey Atkinson
Journal:  Front Pharmacol       Date:  2011-04-27       Impact factor: 5.810

10.  Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 Receptor.

Authors:  Wenjuan Wang; Xiaotang Ma; Jichun Han; Mingjie Zhou; Huanhuan Ren; Qunwen Pan; Chunli Zheng; Qiusheng Zheng
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.